Cleerly LABS vs ElucidVivo A.3
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if your primary objective is a comprehensive, AI-powered analysis of coronary CT angiography (CCTA) for detailed detection, quantification, and characterization of atherosclerosis and stenosis specifically within the coronary arteries. This tool is particularly well-suited for tracking disease progression over time and assessing for ischemia, providing critical insights for personalized heart disease management and guiding medical therapy.
View Cleerly LABS →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require highly quantitative and histologically validated analysis of arterial plaque composition and stability from CT angiography to precisely stratify patients with atherosclerosis. This tool is ideal for quantifying specific plaque components like Lipid-Rich Necrotic Core (LRNC) and aiding in optimizing treatment decisions based on detailed lesion-level characteristics, especially when assessing rupture risk across various arteries.
View ElucidVivo A.3 →When choosing between Cleerly LABS and ElucidVivo A.3, physicians should consider their primary focus in cardiovascular imaging analysis. Both are FDA-cleared AI tools for analyzing CT angiography, but they offer distinct strengths. Cleerly LABS excels in comprehensive coronary plaque assessment, providing detailed quantification of plaque volume and type, stenosis detection, and even ischemia detection with its ISCHEMIA module. It’s designed for personalized heart disease risk assessment and tracking disease progression over time, making it suitable for long-term management and preventative cardiology.
ElucidVivo A.3, on the other hand, specializes in the quantitative analysis of arterial plaque composition and stability, with a unique focus on objectively quantifying specific plaque components like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications. Its key practical difference lies in its validation against histology and its ability to derive fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. This makes ElucidVivo A.3 particularly valuable for stratifying patients with atherosclerosis and optimizing treatment decisions based on plaque vulnerability.
Therefore, a physician prioritizing a broad, longitudinal view of coronary atherosclerosis and overall heart disease risk management might favor Cleerly LABS. Conversely, a physician focused on detailed plaque characterization, stability assessment, and treatment optimization for specific atherosclerotic lesions, especially in vascular surgery or interventional cardiology, would likely find ElucidVivo A.3 more aligned with their needs.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | ElucidVivo A.3 |
|---|---|---|
| Pricing | Varies | Unknown |
| Deployment | Cloud, On-premise | Cloud and on-premise secure deployment. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | ElucidVivo A.3 |
|---|---|---|
| Tool Name | Cleerly LABS | ElucidVivo A.3 |
| Company | Cleerly | Elucid Bioimaging |
| Description | AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. | FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology. |
| Key Features (Plaque Analysis) | Comprehensive coronary plaque assessment (volume, type), Stenosis detection and quantification, Ischemia detection (with Cleerly ISCHEMIA module) | AI-powered quantitative analysis of arterial plaque, Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, Visualizes lesion-level plaque composition |
| Key Features (Visualization) | 3D visualization of coronary arteries | 3D visualization of highlighted vessels, Offers rotatable curved MPR vessel views and cross-sections |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and ElucidVivo A.3.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or ElucidVivo A.3
Backers
Who funded each tool's parent company.